Unity Biotechnology
UBX was delisted on the 8th of July, 2025.
72 hedge funds and large institutions have $24.1M invested in Unity Biotechnology in 2022 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 16 increasing their positions, 12 reducing their positions, and 16 closing their positions.
23,842% more call options, than puts
Call options by funds: $5.75M | Put options by funds: $24K
354% more capital invested
Capital invested by funds: $5.31M → $24.1M (+$18.8M)
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
44% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 16
33% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 12
11% more funds holding
Funds holding: 65 → 72 (+7)
2.99% more ownership
Funds ownership: 1.36% → 4.35% (+3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$8.11M |
| 2 |
AVM
Arch Venture Management
Chicago,
Illinois
|
+$6.34M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.17M |
| 4 |
EAM
Empery Asset Management
New York
|
+$2.78M |
| 5 |
ACM
Altium Capital Management
New York
|
+$2.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$361K |
| 2 |
PVI
Pura Vida Investments
New York
|
-$202K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$141K |
| 4 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
-$127K |
| 5 |
Two Sigma Advisers
New York
|
-$118K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VVP
76
Venture Visionary Partners
Sylvania,
Ohio
| – | -$347 | -62 | Closed |
|
77
Wells Fargo
San Francisco,
California
| – | -$38 | -6 | -6% |
|
78
JP Morgan Chase
New York
| – | +$44 | +7 | New |
|
79
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$170 | +27 | +19% |
|
UBX Hedge Fund Activity: Q3 2022 in Review
72 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Unity Biotechnology (UBX) for Q3 2022, worth a combined $24.1M — up 354% from $5.31M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new UBX positions and 16 closed out — a net gain of 7 holders — while 16 added to existing stakes and 12 trimmed.
The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $8.11M. The largest seller was GSA Capital Partners, exiting entirely with an estimated $361K sold.
- 72 institutional investors held Unity Biotechnology (UBX) as of Q3 2022, up from 65 in Q2 2022.
- Funds reported $24.1M of Unity Biotechnology stock for Q3 2022, up 354% quarter-over-quarter.
- 23 funds opened new Unity Biotechnology positions in Q3 2022 and 16 closed out, a net change of +7 holders.
- The largest Unity Biotechnology buyer in Q3 2022 was Alyeska Investment Group, an estimated $8.11M added.
- The largest Unity Biotechnology seller in Q3 2022 was GSA Capital Partners, an estimated $361K sold.
Based on aggregated 13F filings for Q3 2022.